Environmental lawyer and volunteer riverkeeper RFK jr continues to make waves in his current job as head of the US Health and Human Services Agency. This time, he’s going after psychiatry. MAHA Madness The controversial master falcon keeper who claims to have driven around New York with a dead bear in his car, announced at […]
The post More MAHA Mayhem? appeared first on Medical News Bulletin.
The FDA has approved IV ocrelizumab for treatment of relapsing-remitting MS in children and adolescents aged 10 years and older and weighing at least 55 pounds, according to Genentech.
Ocrelizumab (Ocrevus, Genentech) has previously been approved to treat adults with primary progressive MS, and relapsing forms, including active secondary progressive disease, clinically isolated syndrome and relapsing-remitting disease.
“This approval represents a landmark for children living with MS in the U.S. and their families, which can help close the longstanding gap in high-efficacy treatment
DENVER — Glaucoma and hypertension were both linked with worsened cognitive performance, according to a poster presentation at the Association of Vision and Research in Ophthalmology.
Jason Greenfield, MD, Alon Harris, MD, and Yash Lahoti spoke with Healio about their study, which was designed to look at some of the unknown risk factors for glaucoma.
“Only intraocular pressure is recognized as a treatable risk factor by the FDA,” Harris said. “However, it’s clear that from the plethora of studies that are around there are many different risk factors that play a role in the occurrence, incidence